To evaluate the efficacy and safety of Roujin Formula in the treatment of fibromyalgia syndrome(FMS)patients with blood deficiency and liver depression through a randomized,single-blind,placebo-parallel controlled exploratory clinical trial study,and to provide reliable clinical evidence for the treatment of fibromyalgia syndrome with Roujin Formula. 48 eligible participants with FMS of blood deficiency and liver depression syndrome were selected and randomly divided into treatment group(n=24)and control group(n=24). The treatment group was given Roujin Foumula 150mL,twice a day; The control group was given Roujin Foumula placebo 150mL,twice a day,the study period was 8 weeks. The evaluation points were 0 weeks,4 weeks,and 8 weeks of treatment,and follow-up to 12 weeks. To evaluate the effect changes before and after treatment,FIQR score、VAS score、PSQI score、BDI score and SF-36 PCS、MCS score were used as secondary efficacy evaluation indexes. SPSS23.0 was used to analyze the data.

Inclusion Criteria:

• 1. Meet the 1990 American College of Rheumatology (ACR) Research Classification Criteria for filbromyalgia;
• 2. Be over 18 years of age;
• 3. Sign informed consent.

Exclusion Criteria:

• 1.patients with rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, ankylosing spondylitis and other rheumatic diseases ;
• 2.severe liver and kidney dysfunction;
• 3.severe cardiovascular and cerebrovascular diseases and other diseases ;
• 4.pregnant or lactating women ;
• 5.had taken drugs for the treatment of this disease in the last 4 weeks.